Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant I

ABSTRACT: Global gene expression profiling was performed on OCI-AML2 leukemia cell line, R3 and R50 drug resistant cell lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE108142 | GEO | 2020/08/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant II

Project description:Gene expression profiling was performed on OCI-AML2 R50 drug resistant leukemia cell line before or after Romidepsin treatment.

2020-08-28 | GSE114648 | GEO

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-08-28 | GSE114649 | GEO

Epigenome analysis of parental and ABT-199 resistant AML cell lines

Project description:Genome wide DNA methylation profiling of parental, ABT-199 resistant population, and ABT-199 resistant clones from 3 acute myelogenous leukemia (AML) cell lines (MOLM-13, MV-4-11, OCI-AMLO2). The Illumina Infinium MethylationEPIC Human DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpGs from AML cell line samples. Samples include 4 ABT-199 sensitive parental MOLM-13 population samples, 4 ABT-199 resistant MOLM-13 population samples, 3 ABT-199 resistant MOLM-13 S2 clone samples, 3 ABT-199 resistant MOLM-13 S5 clone samples, 4 ABT-199 resistant MOLM-13 S6 clone samples, 3 ABT-199 sensitive parental MV-4-11 population samples, 3 ABT-199 resistant MV-4-11 population samples, 3 ABT-199 sensitive parental OCI-AML2 population samples, 3 ABT-199 resistant OCI-AML2 population samples, 3 ABT-199 resistant OCI-AML2 S1 clone samples, 3 ABT-199 resistant OCI-AML2 S2 clone samples, 3 ABT-199 resistant OCI-AML2 S8 clone samples.

2022-01-12 | GSE193254 | GEO

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant

Project description:Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant

| PRJNA472052 | ENA

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant II

Project description:Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant II

| PRJNA472053 | ENA

Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant I

Project description:Epigenetic drugs selectively target a population of AML cells which are positive for CD123 cell surface markers and are chemoresistant I

| PRJNA422583 | ENA

Gene expression profiling of AML cell lines treated with nuclear export inhibitor, selinexor

Project description:RNA-seq analysis in OCI-AML2 and MOLM-13 cells treated with selinexor or DMSO for 36 hours.

2022-01-01 | GSE181003 | GEO

RNA-seq expression profiling of OCI-AML2 and OCI-AML3 cells upon CRISPR/Cas9 –mediated disruption of DDX3X RNA binding domain

Project description:Human acute myeloid leukemia cell lines OCI-AML2 and OCI-AML3 were used in a CRISPR/Cas9-mediated approach to specifically target DDX3X’s gene sequences encoding the RNA binding domain of the helicase. DDX3X RNA binding domain is bipartite in the two halves of the helicase core. sgRNAs were designed to target both halves of the domain (named RNA binding domain A and B – RBDA and RBDB). We performed RNA-seq to observe the gene expression changes in both OCI-AML2 and OCI-AML3 cell lines following the not-combined CRISPR/Cas9 –mediated targeting of both regions of the DDX3X RNA binding domain. Control CRISPR/Cas9 performed with no sgRNA expressing vector (named “empty vector”) was performed in both cell lines. The latter condition was used as a control for gene expression changes analysis, for each cell line.

2019-11-23 | E-MTAB-6241 | biostudies-arrayexpress

Transcription profiling of human acute myeloid leukemia cell line OCI/AML2 with the anti-parasitic ivermectin

Project description:OCI AML2 cells were treated with the anti-parasitic ivermectin (single dose, two time points) in order to assess gene expression changes.

2010-01-06 | E-MEXP-2528 | biostudies-arrayexpress

Actinomycin D-induced mitochondrial stress targets PML during NPM1c-AML therapy

Project description:Microarrays transcriptomic data analyses from acute myeloid leukemia cell line OCI-AML2 and primary acute myeloid leukemia cells treated with actinomycin D.

2021-05-10 | E-MTAB-10397 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data